The tumor microenvironment of non-small cell lung cancer impairs immune cell function in people with HIV.

Journal: The Journal of clinical investigation
Published Date:

Abstract

Lung cancer is the leading cause of cancer mortality among people with HIV (PWH), with increased incidence and poor outcomes. This study explored whether the tumor microenvironment (TME) of HIV-associated non-small cell lung cancer (NSCLC) limits tumor-specific immune responses. With a matched cohort of NSCLC samples from PWH and from people without HIV (PWOH), we used imaging mass cytometry, a linear mixed-effects model, and an artificial intelligence-based (AI-based) PageRank mathematical algorithm based on spectral graph theory to demonstrate that HIV-associated tumors have differential distribution of tumor-infiltrating CD8+ and CD4+ T cells, enriched for the expression of programmed cell death 1 (PD-1) and lymphocyte-activating gene 3 (LAG3), as well as activation and proliferation markers. We also demonstrate higher expression of immunoregulatory molecules (PD-L1, PD-L2, B7-H3, B7-H4, IDO1, and VISTA) among tumor-associated macrophages. Discrimination of cells between tumors from PWH versus those from PWOH was confirmed by spectral graph theory with 84.6% accuracy. Furthermore, we noted differences in spatial orientation of immune cells within the TME of PWH compared with PWOH. Additionally, cells from PWH, compared with those from PWOH, exhibited decreased tumor killing when exposed to HLA-matched NSCLC cell lines. In conclusion, our study demonstrates that the HIV-associated TME sustained a unique immune landscape, showing evidence of immune cells with enhanced immunoregulatory phenotypes and impaired antitumor responses, with implications for responses to immune checkpoint blocker therapies.

Authors

  • Shruti S Desai
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Syim Salahuddin
    Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Ramsey Yusuf
    Yale University School of Medicine, New Haven, Connecticut, USA.
  • Kishu Ranjan
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Jianlei Gu
    Department of Biostatistics and.
  • Lais Osmani
    Department of Internal Medicine, Section of Rheumatology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Ya-Wei Lin
    Department of Electrical and Computer Engineering Technion-Israel Institute of Technology, Haifa, Israel.
  • Sameet Mehta
    Yale Center for Genome Analysis, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Ronan Talmon
    Department of Electrical and Computer Engineering Technion-Israel Institute of Technology, Haifa, Israel.
  • Insoo Kang
    Department of Internal Medicine, Section of Rheumatology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Yuval Kluger
    Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.
  • Hongyu Zhao
    SJTU-Yale Joint Center for Biostatistics, Shanghai Jiao Tong University, 800 Dong Chuan Road, Shanghai 200240, China; Department of Biostatistics, Yale University, New Heaven, USA.
  • Kurt Schalper
    Department of Pathology, School of Medicine, Yale University, New Haven, Connecticut, United States of America.
  • Brinda Emu
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.